Henrik Lövborg
Impact in
- Toxicology top 5%
- Geriatrics and Gerontology top 10%
Papers in
-
- Cancer therapeutics and mechanisms 4
- Ubiquitin and proteasome pathways 4
- Glycosylation and Glycoproteins Research 3
- Cell death mechanisms and regulation 3
- Oncology 8
- Co-authors
- Rolf Larsson (15 shared papers)Joachim Gullbo (12 shared papers)Peter Nygren (10 shared papers)Linda Rickardson (7 shared papers)Malin Wickström (4 shared papers)Anders Isaksson (4 shared papers)Robert Burman (2 shared papers)Sunithi Gunasekera (1 shared paper)
In The Last Decade
Henrik Lövborg
25 papers receiving 704 citations
Peers
Comparison fields: 5 of 101
- Toxicology 41
- Geriatrics and Gerontology 35
- Oncology 178
- Molecular Biology 435
- Cancer Research 70
Countries citing papers authored by Henrik Lövborg
This map shows the geographic impact of Henrik Lövborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Henrik Lövborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Henrik Lövborg more than expected).
Fields of papers citing papers by Henrik Lövborg
This network shows the impact of papers produced by Henrik Lövborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Henrik Lövborg. The network helps show where Henrik Lövborg may publish in the future.
Co-authors
The 25 scholars most cited alongside Henrik Lövborg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 26 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | 2007 | 110 | |
| 2 | 2005 | 102 | |
| 3 | 2006 | 93 | |
| 4 | 2005 | 67 | |
| 5 | 2004 | 43 | |
| 6 | 2007 | 38 | |
| 7 | 2007 | 33 | |
| 8 | 2006 | 31 | |
| 9 | Identification and evaluation of potential anti-cancer drugs on human neuroendocrine tumor cell lines. | 2007 | 29 |
| 10 | Utilization of a right-handed coiled-coil protein from archaebacterium Staphylothermus marinus as a carrier for cisplatin. | 2009 | 25 |
| 11 | 2012 | 21 | |
| 12 | Action of a novel anticancer agent, CHS 828, on mouse fibroblasts: increased sensitivity of cells lacking poly (ADP-Ribose) polymerase-1. | 2002 | 18 |
| 13 | 2006 | 17 | |
| 14 | 2015 | 15 | |
| 15 | 2017 | 15 | |
| 16 | 2012 | 13 | |
| 17 | 2002 | 11 | |
| 18 | 2014 | 9 | |
| 19 | Antitumor activity of the novel melphalan containing tripeptide J3 (L-prolyl-L-melphalanyl-p-L-fluorophenylalanine ethyl ester): comparison with its m-L-sarcolysin analogue P2. | 2003 | 7 |
| 20 | CHS 828 kill tumour cells by inhibiting the nuclear factor-kappaB translocation but unlikely through down-regulation of proteasome. | 2007 | 7 |
About Henrik Lövborg
Henrik Lövborg is a scholar working on Molecular Biology, Oncology, Toxicology, Pharmacology and Pharmacology, having authored 26 papers that have together received 720 indexed citations. Recurring topics across this work include Pharmacovigilance and Adverse Drug Reactions (4 papers), Cancer therapeutics and mechanisms (4 papers), Ubiquitin and proteasome pathways (4 papers), Cancer Research and Treatments (3 papers), Glycosylation and Glycoproteins Research (3 papers), Cell death mechanisms and regulation (3 papers), Pharmaceutical Practices and Patient Outcomes (2 papers) and Neuroblastoma Research and Treatments (2 papers). The work is most often cited by research in Toxicology (41 citations), Geriatrics and Gerontology (35 citations), Oncology (178 citations), Molecular Biology (435 citations) and Cancer Research (70 citations). Henrik Lövborg has collaborated with scholars based in Sweden, Germany and Austria. Frequent co-authors include Rolf Larsson, Joachim Gullbo, Peter Nygren, Linda Rickardson, Malin Wickström, Anders Isaksson, Robert Burman, Sunithi Gunasekera, Erika Svangård and Ulf Göransson. Their work appears in journals such as Biochemical Pharmacology, SLAS DISCOVERY, Molecular Cancer Therapeutics, European Journal of Clinical Pharmacology and British Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.